Clinuvel Pharmaceuticals Limited Share Price
Stocks
CUV
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.08 AUD | +1.31% |
|
+2.56% | -19.50% |
| 06-16 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 04-28 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| Market Cap | 502M 348M 305M 281M 263M 493M 32.92B 3.38B 1.31B 16.15B 1.3B 1.28B 56.14B | P/E 2026 * |
14x | P/E 2027 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise Value | 248M 172M 151M 139M 130M 244M 16.28B 1.67B 646M 7.99B 645M 631M 27.76B | EV / Sales 2026 * |
2.49x | EV / Sales 2027 * | 2.05x |
| Free-Float |
83.79% | Yield 2026 * |
0.61% | Yield 2027 * | 0.8% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +0.80% | ||
| 1 week | +2.56% | ||
| Current month | +9.86% | ||
| 1 month | +13.08% | ||
| 3 months | +4.15% | ||
| 6 months | -21.52% | ||
| Current year | -19.50% |
| 1 week | 9.73 |  | 10.3 |
| 1 month | 8.35 | | 10.3 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.1 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 31/10/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 29/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Guy van Dievoet
BRD | Director/Board Member | - | 05/09/2024 |
Karen Agersborg
BRD | Director/Board Member | - | 28/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 22/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 26/11/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 26/11/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.31% | +2.56% | +0.10% | -41.92% | 359M | |
| +0.90% | +0.54% | +20.73% | -20.74% | 62.32B | |
| +1.66% | +0.68% | +53.10% | +200.79% | 53.94B | |
| -1.70% | +27.30% | +27.30% | +27.30% | 38.98B | |
| +2.51% | +7.51% | -52.41% | -59.00% | 37.89B | |
| -1.26% | +0.81% | +58.06% | -30.69% | 29.48B | |
| +2.79% | +10.11% | +137.63% | -48.52% | 23.55B | |
| +0.71% | +4.66% | +55.22% | +67.17% | 20.71B | |
| +1.53% | +0.13% | -3.04% | +151.23% | 16.71B | |
| +4.86% | +8.36% | +68.50% | +121.25% | 16.02B | |
| Average | +1.28% | +2.32% | +36.52% | +36.69% | 30B | |
| Weighted average by Cap. | +1.07% | +1.17% | +34.59% | +40.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 68.89M 60.52M 55.77M 52.21M 97.81M 6.53B 670M 259M 3.2B 259M 253M 11.13B | 105M 72.98M 64.11M 59.07M 55.3M 104M 6.91B 709M 275M 3.39B 274M 268M 11.79B |
| Net income | 35.97M 24.91M 21.89M 20.17M 18.88M 35.37M 2.36B 242M 93.73M 1.16B 93.52M 91.51M 4.02B | 38.2M 26.46M 23.24M 21.42M 20.05M 37.57M 2.51B 257M 99.55M 1.23B 99.33M 97.19M 4.27B |
| Net Debt | -254M -176M -154M -142M -133M -249M -16.65B -1.71B -661M -8.17B -660M -645M -28.39B | -286M -198M -174M -160M -150M -281M -18.77B -1.93B -745M -9.21B -744M -728M -32.01B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/06/26 | A$10.08 | +1.31% | 12,829 |
| 23/06/26 | A$9.950 | -2.16% | 95,007 |
| 22/06/26 | A$10.17 | -1.26% | 72,231 |
| 19/06/26 | A$10.30 | +3.73% | 278,606 |
| 18/06/26 | A$9.930 | +1.53% | 158,140 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
